{"id":"https://openalex.org/W4283208488","doi":"https://doi.org/10.1007/s12325-022-02201-6","title":"Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States","display_name":"Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States","alternate_titles":[],"publication_year":2022,"publication_date":"2022-06-21","ids":{"openalex":"https://openalex.org/W4283208488","doi":"https://doi.org/10.1007/s12325-022-02201-6","pmid":"https://pubmed.ncbi.nlm.nih.gov/35727476","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/9309154"},"language":"en","primary_location":{"id":"doi:10.1007/s12325-022-02201-6","doi":"https://doi.org/10.1007/s12325-022-02201-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s12325-022-02201-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s12325-022-02201-6.pdf","source":{"id":"https://openalex.org/S27230875","display_name":"Advances in Therapy","issn_l":"0741-238X","issn":["0741-238X","1865-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4283208488"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://link.springer.com/content/pdf/10.1007/s12325-022-02201-6.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5025137989","display_name":"Bijal Dinesh Shah","orcid":"https://orcid.org/0000-0003-4328-6021","observed_orcids":["https://orcid.org/0000-0003-4328-6021"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bijal D. Shah","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL, USA","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101772448","display_name":"Nathaniel Smith","orcid":"https://orcid.org/0000-0002-9215-8109","observed_orcids":["https://orcid.org/0000-0002-9215-8109"]},"institutions":[],"countries":[],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Nathaniel J. Smith","raw_affiliation_strings":["Maple Health Group, LLC, 1740 Broadway, 15th Floor, New York, NY, 10019, USA. nate.smith@maplehealthgroup.com","Maple Health Group, LLC, 1740 Broadway, 15th Floor, New York, NY, 10019, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Maple Health Group, LLC, 1740 Broadway, 15th Floor, New York, NY, 10019, USA. nate.smith@maplehealthgroup.com","institution_ids":[]},{"raw_affiliation_string":"Maple Health Group, LLC, 1740 Broadway, 15th Floor, New York, NY, 10019, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050095307","display_name":"Chaoling Feng","orcid":"https://orcid.org/0000-0003-4654-4305","observed_orcids":["https://orcid.org/0000-0003-4654-4305"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Chaoling Feng","raw_affiliation_strings":["Kite, A Gilead Company, Santa Monica, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kite, A Gilead Company, Santa Monica, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045200701","display_name":"Sushanth Jeyakumar","orcid":"https://orcid.org/0000-0001-8116-9673","observed_orcids":["https://orcid.org/0000-0001-8116-9673"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sushanth Jeyakumar","raw_affiliation_strings":["Maple Health Group, LLC, 1740 Broadway, 15th Floor, New York, NY, 10019, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Maple Health Group, LLC, 1740 Broadway, 15th Floor, New York, NY, 10019, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110035836","display_name":"Jean\u2010Gabriel Castaigne","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106787","display_name":"Gilead Sciences (United Kingdom)","ror":"https://ror.org/01e11zd27","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210106787","https://openalex.org/I4210140816"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jean-Gabriel Castaigne","raw_affiliation_strings":["Kite, A Gilead Company, Uxbridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kite, A Gilead Company, Uxbridge, UK","institution_ids":["https://openalex.org/I4210106787"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112755914","display_name":"Imi Faghmous","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210106787","display_name":"Gilead Sciences (United Kingdom)","ror":"https://ror.org/01e11zd27","country_code":"GB","type":"company","lineage":["https://openalex.org/I4210106787","https://openalex.org/I4210140816"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Imi Faghmous","raw_affiliation_strings":["Kite, A Gilead Company, Uxbridge, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kite, A Gilead Company, Uxbridge, UK","institution_ids":["https://openalex.org/I4210106787"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081793914","display_name":"Behzad Kharabi Masouleh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Behzad Kharabi Masouleh","raw_affiliation_strings":["Kite, A Gilead Company, Santa Monica, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Kite, A Gilead Company, Santa Monica, CA, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067710734","display_name":"Daniel C. Malone","orcid":"https://orcid.org/0000-0002-5006-9394","observed_orcids":["https://orcid.org/0000-0002-5006-9394"]},"institutions":[{"id":"https://openalex.org/I223532165","display_name":"University of Utah","ror":"https://ror.org/03r0ha626","country_code":"US","type":"education","lineage":["https://openalex.org/I223532165"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Daniel C. Malone","raw_affiliation_strings":["University of Utah, Salt Lake City, UT, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Utah, Salt Lake City, UT, USA","institution_ids":["https://openalex.org/I223532165"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108355038","display_name":"Michael Russell Bishop","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I40347166","display_name":"University of Chicago","ror":"https://ror.org/024mw5h28","country_code":"US","type":"education","lineage":["https://openalex.org/I40347166"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael R. Bishop","raw_affiliation_strings":["The David Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The David Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL, USA","institution_ids":["https://openalex.org/I40347166"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5101772448"],"corresponding_institution_ids":[],"apc_list":{"value":4190,"currency":"USD","value_usd":4190},"apc_paid":{"value":4190,"currency":"USD","value_usd":4190},"fwci":1.5762,"has_fulltext":true,"cited_by_count":17,"citation_normalized_percentile":{"value":0.85232859,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"39","issue":"8","first_page":"3678","last_page":"3695"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.7968999743461609,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},"topics":[{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.7968999743461609,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}},{"id":"https://openalex.org/T10950","display_name":"Acute Lymphoblastic Leukemia research","score":0.09969999641180038,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.05660000070929527,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/relapsed-refractory-b-cell-acute-lymphoblastic-leukemia","display_name":"relapsed/refractory B-cell acute lymphoblastic leukemia","score":0.9309999942779541},{"id":"https://openalex.org/keywords/car-t-cell-therapy","display_name":"CAR T-cell therapy","score":0.8600000143051147},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.9769999980926514},{"id":"https://openalex.org/keywords/quality-adjusted-life-years","display_name":"quality-adjusted life years","score":0.8479999899864197},{"id":"https://openalex.org/keywords/incremental-cost-effectiveness-ratio","display_name":"incremental cost-effectiveness ratio","score":0.878000020980835},{"id":"https://openalex.org/keywords/blinatumomab","display_name":"blinatumomab","score":0.9049999713897705},{"id":"https://openalex.org/keywords/inotuzumab-ozogamicin","display_name":"inotuzumab ozogamicin","score":0.9980000257492065},{"id":"https://openalex.org/keywords/salvage-chemotherapy","display_name":"salvage chemotherapy","score":0.9940000176429749},{"id":"https://openalex.org/keywords/allogeneic-stem-cell-transplantation","display_name":"allogeneic stem cell transplantation","score":0.8610000014305115},{"id":"https://openalex.org/keywords/healthcare-resource-utilization","display_name":"healthcare resource utilization","score":0.5350000262260437}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8442548513412476},{"id":"https://openalex.org/C64332521","wikidata":"https://www.wikidata.org/wiki/Q614165","display_name":"Quality-adjusted life year","level":3,"score":0.5759506821632385},{"id":"https://openalex.org/C3019080777","wikidata":"https://www.wikidata.org/wiki/Q1754768","display_name":"Cost effectiveness","level":2,"score":0.42329972982406616},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3973342478275299},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.35497528314590454},{"id":"https://openalex.org/C112930515","wikidata":"https://www.wikidata.org/wiki/Q4389547","display_name":"Risk analysis (engineering)","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000076962","descriptor_name":"Receptors, Chimeric Antigen","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000080045","descriptor_name":"Inotuzumab Ozogamicin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003362","descriptor_name":"Cost-Benefit Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016219","descriptor_name":"Immunotherapy, Adoptive","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D016393","descriptor_name":"Lymphoma, B-Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019057","descriptor_name":"Quality-Adjusted Life Years","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054198","descriptor_name":"Precursor Cell Lymphoblastic Leukemia-Lymphoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true}],"locations_count":3,"locations":[{"id":"doi:10.1007/s12325-022-02201-6","doi":"https://doi.org/10.1007/s12325-022-02201-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s12325-022-02201-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s12325-022-02201-6.pdf","source":{"id":"https://openalex.org/S27230875","display_name":"Advances in Therapy","issn_l":"0741-238X","issn":["0741-238X","1865-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in Therapy","raw_type":"journal-article"},{"id":"pmid:35727476","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/35727476","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in therapy","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:9309154","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9309154/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Adv Ther","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1007/s12325-022-02201-6","doi":"https://doi.org/10.1007/s12325-022-02201-6","is_oa":true,"landing_page_url":"https://doi.org/10.1007/s12325-022-02201-6","pdf_url":"https://link.springer.com/content/pdf/10.1007/s12325-022-02201-6.pdf","source":{"id":"https://openalex.org/S27230875","display_name":"Advances in Therapy","issn_l":"0741-238X","issn":["0741-238X","1865-8652"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320330","host_organization_name":"Adis, Springer Healthcare","host_organization_lineage":["https://openalex.org/P4310320330","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Adis, Springer Healthcare","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Advances in Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320308573","display_name":"Gilead Sciences","ror":"https://ror.org/056546b03"},{"id":"https://openalex.org/F4320333647","display_name":"Kite Pharma","ror":"https://ror.org/05waa9105"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4283208488.pdf","grobid_xml":"https://content.openalex.org/works/W4283208488.grobid-xml"},"referenced_works_count":33,"referenced_works":["https://openalex.org/W1512398135","https://openalex.org/W1701044074","https://openalex.org/W1784814409","https://openalex.org/W1982967337","https://openalex.org/W2076003266","https://openalex.org/W2078074124","https://openalex.org/W2096552494","https://openalex.org/W2123974278","https://openalex.org/W2164665019","https://openalex.org/W2170239385","https://openalex.org/W2277431766","https://openalex.org/W2516611622","https://openalex.org/W2591709377","https://openalex.org/W2787301955","https://openalex.org/W2809572695","https://openalex.org/W2884909078","https://openalex.org/W2889753173","https://openalex.org/W2904009339","https://openalex.org/W2904940919","https://openalex.org/W2931981435","https://openalex.org/W2950219174","https://openalex.org/W2999417355","https://openalex.org/W3006266640","https://openalex.org/W3018120101","https://openalex.org/W3033565404","https://openalex.org/W3113143481","https://openalex.org/W3130692824","https://openalex.org/W3169193862","https://openalex.org/W3177313466","https://openalex.org/W3198687777","https://openalex.org/W3211929629","https://openalex.org/W3213743659","https://openalex.org/W6678266410"],"related_works":["https://openalex.org/W3198687777","https://openalex.org/W6939425275","https://openalex.org/W3130692824","https://openalex.org/W4381245411","https://openalex.org/W2922233418","https://openalex.org/W4390127741","https://openalex.org/W3114779946","https://openalex.org/W7134123240","https://openalex.org/W4401752195","https://openalex.org/W2893003701"],"abstract_inverted_index":{"Despite":[0],"currently":[1],"available":[2,139,406],"treatments":[3,295],"for":[4,20,52,190,281,296,334,479],"adults":[5,33,282,297],"with":[6,34,283,298,330,438,456],"relapsed/refractory":[7,299],"acute":[8,302],"lymphoblastic":[9,303],"leukemia":[10,304],"(R/R":[11,305],"ALL),":[12],"survival":[13,67,333],"outcomes":[14],"remain":[15],"poor,":[16],"highlighting":[17],"the":[18,27,76,125,185,311,315,326,350,376,401,411,502],"need":[19],"new":[21],"therapeutic":[22],"strategies.":[23],"This":[24,372],"study":[25],"estimates":[26],"cost-effectiveness":[28,168,484],"of":[29,87,149,214,269,382,413,434,444,461,486],"KTE-X19":[30,59,71,150,191,245,271,286,383,429,457,472],"to":[31,109,232,252,278,360,424,475,506,514],"treat":[32],"R/R":[35,284],"ALL":[36],"from":[37,124,135,397],"a":[38,47,65,265,414,420],"US":[39,415],"payer":[40,418],"perspective.":[41],"The":[42,408],"model":[43,110,373,409],"had":[44,458],"two":[45],"components:":[46],"decision-tree,":[48],"where":[49,69],"pre-infusion":[50],"costs":[51,143,204,328,460],"patients":[53,73,335],"who":[54],"ultimately":[55],"did":[56],"not":[57,368],"receive":[58],"are":[60,153,499],"accounted":[61],"for,":[62],"followed":[63],"by":[64,291,349],"partitioned":[66],"analysis,":[68],"all":[70,275],"infused":[72],"would":[74],"enter":[75],"three-state":[77],"(pre-progression,":[78],"progressed":[79],"disease,":[80],"death)":[81],"model.":[82],"Comparators":[83],"included":[84],"current":[85,279,385],"standard":[86,101],"care":[88],"treatments,":[89,332,386],"i.e.,":[90],"blinatumomab":[91,318],"(BLIN),":[92],"inotuzumab":[93,321],"ozogamicin":[94,322],"(INO),":[95],"and":[96,103,117,129,142,157,165,172,177,195,200,208,221,239,249,258,320,352,379,390,403,427,451,468,493,519],"salvage":[97,391],"chemotherapy":[98,392],"(CHEMO).":[99,393],"Both":[100],"parametric":[102],"mixture":[104],"cure":[105],"models":[106],"were":[107,122,133,144,181,192,205,229,395,511],"used":[108,410],"survival.":[111,293],"Efficacy,":[112],"safety,":[113],"healthcare":[114],"resource":[115],"utilization,":[116],"health":[118],"state":[119],"utility":[120],"inputs":[121,132],"derived":[123,134,396],"ZUMA-3":[126],"trial":[127],"(NCT02614066)":[128],"literature.":[130],"Cost":[131],"literature":[136],"or":[137],"publicly":[138,405],"sources.":[140,407],"Outcomes":[141],"discounted":[145],"3%":[146],"annually.":[147],"Results":[148,510],"versus":[151,197,255,274,384],"comparators":[152],"reported":[154],"as":[155,436],"total":[156],"incremental":[158,167,188,439,459,483],"life-years":[159,162],"(LYs),":[160],"quality-adjusted":[161,440],"(QALYs),":[163],"costs,":[164],"resulting":[166,211],"ratio":[169],"(ICER).":[170],"Deterministic":[171,225],"probabilistic":[173],"sensitivity":[174,226,518],"analyses":[175,180],"(PSA)":[176],"key":[178,398],"scenario":[179,520],"also":[182,512],"performed.":[183],"In":[184],"base":[186],"case,":[187],"QALYs":[189],"2.44,":[193],"3.26,":[194],"4.61":[196,452],"BLIN,":[198,256,388,425],"INO,":[199,257,389],"CHEMO,":[201,259,428],"respectively.":[202,260],"Incremental":[203],"$50,913,":[206],"$251,532,":[207],"$432,027,":[209],"respectively,":[210],"in":[212,310,314,355,431],"ICERs":[213],"$20,843/QALY":[215,487],"(versus":[216,219,223],"BLIN),":[217,447,464,489],"$77,271/QALY":[218,490],"INO),":[220,450,467,492],"$93,768/QALY":[222,494],"CHEMO).":[224,454,471,496],"analysis":[227],"results":[228],"most":[230,262],"sensitive":[231],"subsequent":[233],"allogeneic":[234],"stem":[235],"cell":[236],"transplant":[237],"rates":[238],"post-progression":[240],"utilities.":[241],"PSA":[242],"found":[243,474,513],"that":[244],"is":[246,287],"78.4%,":[247],"74.0%,":[248],"75.4%":[250],"likely":[251],"be":[253,515],"cost-effective":[254,273],"Across":[261],"scenarios,":[263],"at":[264],"willingness-to-pay":[266],"(WTP)":[267],"threshold":[268],"$150,000/QALY,":[270],"was":[272,473],"treatments.":[276],"Compared":[277,423],"options":[280],"ALL,":[285],"cost-effective,":[288],"driven":[289],"primarily":[290],"improved":[292,432],"Several":[294],"B-cell":[300],"precursor":[301],"B-ALL)":[306],"have":[307],"been":[308,370],"approved":[309,348],"past":[312],"decade":[313],"US,":[316],"including":[317,387],"(BLIN)":[319],"(INO).":[323],"However,":[324],"despite":[325],"high":[327],"associated":[329],"these":[331],"remains":[336],"poor.":[337],"KTE-X19,":[338],"an":[339],"autologous":[340],"anti-CD19":[341],"chimeric":[342],"antigen":[343],"receptor":[344],"T-cell":[345],"(CAR-T)":[346],"therapy,":[347],"Food":[351],"Drug":[353],"Administration":[354],"October":[356],"2021,":[357],"has":[358,367],"potential":[359],"improve":[361],"survival,":[362],"but":[363],"its":[364],"economic":[365,380,508],"value":[366,381,478],"yet":[369],"determined.":[371],"comprehensively":[374],"evaluated":[375],"long-term":[377],"clinical":[378,399],"Inputs":[394],"trials,":[400],"literature,":[402],"other":[404],"perspective":[412],"third":[416],"party":[417],"over":[419],"patient":[421],"lifetime.":[422],"INO":[426],"resulted":[430],"quality":[433],"life":[435,441],"measured":[437],"years":[442],"(QALYs)":[443],"2.44":[445],"(vs":[446,449,453,463,466,470,488,491,495],"3.26":[448],"Treatment":[455],"$50,913":[462],"$251,532":[465],"$432,027":[469],"provide":[476],"good":[477],"money":[480],"based":[481],"on":[482],"ratios":[485],"These":[497],"values":[498],"well":[500],"below":[501],"commonly":[503],"accepted":[504],"thresholds":[505],"determine":[507],"value.":[509],"robust":[516],"across":[517],"analyses.":[521]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4283208488","counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":2}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2022-06-22T00:00:00"}
